BidaskClub cut shares of Accuray Incorporated (NASDAQ:ARAY) from a hold rating to a sell rating in a research note issued to investors on Thursday, July 27th.
A number of other equities research analysts have also weighed in on ARAY. Zacks Investment Research raised shares of Accuray from a strong sell rating to a hold rating in a report on Monday, July 17th. Jefferies Group LLC reissued a buy rating and set a $7.00 target price on shares of Accuray in a report on Friday, June 30th. Finally, BTIG Research reaffirmed a hold rating on shares of Accuray in a research note on Sunday, April 30th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $7.04.
Accuray (ARAY) opened at 4.00 on Thursday. The firm has a 50-day moving average price of $4.42 and a 200-day moving average price of $4.66. The firm’s market capitalization is $332.00 million. Accuray has a 52 week low of $3.85 and a 52 week high of $6.39.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Accuray during the fourth quarter valued at $9,179,000. Neuberger Berman Group LLC raised its stake in Accuray by 26.7% in the first quarter. Neuberger Berman Group LLC now owns 5,014,941 shares of the medical equipment provider’s stock valued at $23,821,000 after buying an additional 1,057,654 shares during the last quarter. Vident Investment Advisory LLC raised its stake in Accuray by 212.7% in the first quarter. Vident Investment Advisory LLC now owns 1,553,111 shares of the medical equipment provider’s stock valued at $7,377,000 after buying an additional 1,056,395 shares during the last quarter. Bogle Investment Management L P DE purchased a new stake in Accuray during the first quarter valued at about $1,952,000. Finally, Vanguard Group Inc. raised its stake in Accuray by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock valued at $30,623,000 after buying an additional 286,011 shares during the last quarter. Hedge funds and other institutional investors own 82.74% of the company’s stock.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
